Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deciphering erectile dysfunction drug trials.

John P Mulhall1

  • 1Department of Urology, Weill Medical College of Cornell University, New York Presbyterian Hospital and Memorial Sloan Kettering Cancer Center, New York, New York 10021-4870, USA.

The Journal of Urology
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials.

The journal of sexual medicine·2026
Same author

Selective pump replacement for inflatable penile prosthesis malfunction.

The journal of sexual medicine·2026
Same author

Predictors of clomiphene citrate response in the treatment of men with testosterone deficiency.

The journal of sexual medicine·2026
Same author

Prevalence and predictors of bone density loss in men with low testosterone.

The journal of sexual medicine·2026
Same author

Extended corporal dilation decreases the need for intraoperative adjuvant maneuvers for residual curvature after inflatable penile implant placement in men with Peyronie's disease.

The journal of sexual medicine·2026
Same author

The burden of Peyronie's disease on the female partner: a qualitative study.

The journal of sexual medicine·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
Same journal

With great cost comes great responsibility: who will own the rising costs of bladder cancer care?

The Journal of urology·2026
See all related articles

Interpreting erectile dysfunction drug trial data requires careful assessment of trial design, patient selection, and outcome measures. Clinicians must understand these factors to evaluate new erectogenic medications effectively.

Area of Science:

  • Urology
  • Pharmacology
  • Clinical Trials

Background:

  • Erectile dysfunction (ED) impacts over 20 million men in the U.S.
  • Numerous novel erectogenic agents are under development.
  • Urologists need expertise in analyzing data from ED drug trials.

Purpose of the Study:

  • To review key data analysis points for novel FDA-approved erectogenic drugs.
  • To guide clinicians in interpreting clinical trial results for ED medications.

Main Methods:

  • Comprehensive literature review of FDA-approved erectogenic drugs.
  • Utilized MEDLINE database for study selection.
  • Focused on critical data analysis parameters from clinical trials.

Main Results:

Related Experiment Videos

  • Key analysis points include trial design, patient population, endpoints, and adverse events.
  • Patient populations should be representative of the general ED demographic.
  • Validated instruments like the International Index of Erectile Function (IIEF) are crucial for outcome assessment.
  • Adverse event analysis involves frequency, severity, and duration.

Conclusions:

  • Accurate interpretation of ED drug trial data necessitates evaluation of trial design.
  • Careful patient enrollment and outcome analysis are essential.
  • Understanding these factors aids in assessing the efficacy and safety of new erectogenic agents.